LRRK2 and Alzheimer disease: In accordance with these findings, we recently showed that LRRK2 pharmacological inhibition attenuates Aβ1-42-induced astrocytic inflammation and favors the clearance of Aβ1-42 fibrils in cultured cells [11], thus linking LRRK2-mediated inflammation to AD pathology.